Internal Medicine, Hematology & Oncology · Goldsboro, NC
NPI
1316986425
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
203 Cox Blvd
Goldsboro, NC, 27534
Phone (919) 580-0000
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.8M
236,655 services
Medicare patients, 2024
1,155
Average age 75
Drug cost, 2024
$5.3M
2,205 prescriptions
Company payments, 2025
$1,992
From 27 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jason K Boyd was code J1439 (injection, ferric carboxymaltose, 1 mg), 49,500 times for 55 patients. In total Jason K Boyd billed 236,655 services in 152 codes, and Medicare paid $2.8M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-03-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 49,500 | 55 | $0.87 | $43K |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 39,780 | 64 | $0.28 | $11K |
| J0897 Injection, denosumab, 1 mg | Office | 14,528 | 157 | $19.88 | $289K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 13,101 | 24 | $2.33 | $30K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 11,100 | 17 | $0.05 | $580 |
| J1453 Injection, fosaprepitant, 1 mg | Office | 6,600 | 19 | $0.10 | $674 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 2,800 | 28 | $14.74 | $41K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,714 | 80 | $0.09 | $238 |
| J3245 Injection, tildrakizumab, 1 mg | Office | 2,300 | 11 | $107.60 | $247K |
| 85025 Blood Count | Office | 2,222 | 756 | $7.55 | $17K |
| J0461 Injection, atropine sulfate, 0.01 mg | Office | 1,640 | 17 | $0.07 | $110 |
| Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 1,460 | 12 | $31.81 | $46K |
| 36415 Venipuncture Blood Collection | Office | 1,397 | 734 | $7.83 | $11K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,380 | 57 | $0.70 | $970 |
| 80053 Clinical Chemistry | Office | 1,066 | 589 | $10.26 | $11K |
By year: 2022 $2.6M for 245,638 services; 2023 $2.7M for 165,897 services; 2024 $2.8M for 236,655 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,222 | 756 | $7.55 | $17K |
| 36415 Venipuncture Blood Collection | 1,397 | 734 | $7.83 | $11K |
| 80053 Clinical Chemistry | 1,066 | 589 | $10.26 | $11K |
| 82728 Clinical Chemistry | 367 | 242 | $13.29 | $4,876 |
| 83540 Clinical Chemistry | 205 | 175 | $6.31 | $1,293 |
| 83550 Clinical Chemistry | 205 | 175 | $8.53 | $1,748 |
| 83735 Clinical Chemistry | 192 | 81 | $6.57 | $1,261 |
| 85610 Clinical Chemistry | 116 | 15 | $4.20 | $487 |
| 81001 Clinical Chemistry | 93 | 48 | $3.08 | $286 |
Medicare prescription drug claims, 2024
In 2024, the drug Jason K Boyd prescribed most often to Medicare patients was Anastrozole, with 182 prescriptions and refills. In total Jason K Boyd wrote 2,205 Medicare prescriptions that cost $5.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 182 | 307 | 38 | $2,239 |
| Tamoxifen Citrate Generic | 123 | 200 | 23 | $2,124 |
| Hydroxyurea Generic | 106 | 157 | 22 | $2,391 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 105 | 105 | 30 | $3,230 |
| Prolia Denosumab | 93 | 557 | 61 | $157K |
| Promethazine Hcl Generic | 71 | 72 | 37 | $1,175 |
| Ondansetron Hcl Generic | 70 | 72 | 39 | $1,809 |
| Eliquis Apixaban | 66 | 66 | 15 | $38K |
| Warfarin Sodium Generic | 63 | 84 | Under 11 | $372 |
| Potassium Chloride Generic | 60 | 64 | 27 | $488 |
| Gabapentin Generic | 59 | 61 | 15 | $463 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 54 | 54 | 12 | $2,308 |
| Megestrol Acetate Generic | 51 | 56 | 19 | $3,212 |
| Xtandi Enzalutamide | 49 | 49 | Under 11 | $664K |
| Xarelto Rivaroxaban | 49 | 65 | Under 11 | $35K |
Brand drugs: - claims; generic drugs: 1,554 claims; opioid claims: 269.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jason K Boyd $1,992 ($1,992 in general payments such as food, travel and fees) from 27 companies. The largest payer was Novartis Pharmaceuticals Corporation with $1,180.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 12 | $1,180 |
| Merck Sharp & Dohme LLC MRK | 4 | $97.93 |
| Genmab U.S., Inc. GMAB | 3 | $75.74 |
| Pfizer Inc. PFE | 3 | $67.44 |
| Taiho Oncology, Inc. 4578.T | 1 | $49.4 |
| Janssen Biotech, Inc. JNJ | 2 | $48.05 |
| Regeneron Healthcare Solutions, Inc. REGN | 2 | $45.16 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $44.25 |
| Geron Corporation GERN | 2 | $39.55 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 1 | $32.9 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.